Satellos Bioscience Announces Joint Development Agreement with NW PharmaTech Limited for Oral CBD
Toronto, Ontario--(Newsfile Corp. - August 18, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics, Inc., and NW PharmaTech Limited ("NW PharmaTech") announced today that Amphotericin B Technologies, Inc. ("AmpB Tech"), a wholly owned subsidiary of Satellos established to accelerate the development of its novel and proprietary oral transport technology ("OralTransTM"), has entered into a Joint Development Agreement with NW PharmaTech to develop an oral...
2021-08-18 4:05 PM EDT
Satellos and iCo Announce Completion of Reverse Takeover
Toronto, Ontario--(Newsfile Corp. - August 13, 2021) - Satellos Bioscience Inc. (formerly iCo Therapeutics Inc.) (TSXV: MSCL) ("Satellos" or the "Company") is pleased to announce the completion, following the receipt of the final order of the Supreme Court of British Columbia on August 5, 2021, and subject to the final approval of the TSX Venture Exchange (the "TSXV"), of the previously announced reverse takeover transaction which was completed by way of plan of arrangement under Section 192...
2021-08-13 6:28 PM EDT
iCo Therapeutics Inc. Announces Shareholder Approval of Business Combination with Satellos Bioscience Inc.
Vancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") is pleased to announce that at an annual and special meeting of the Company held on August 3, 2021, shareholders of the Company have approved, among other matters, iCo's proposed business combination (the "Transaction") with Satellos Bioscience Inc. ("Satellos").The Company expects trading of the shares of the combined company to begin trading on the TSX...
2021-08-05 5:32 PM EDT
iCo Therapeutics Inc. Announces TSX Venture Exchange Conditional Approval and Provides Update Regarding Business Combination with Satellos Bioscience Inc.
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") is pleased to announce that the Company has received formal conditional approval from the TSX Venture Exchange (the "Exchange") of iCo's proposed business combination (the "Transaction") with Satellos Bioscience Inc. ("Satellos").The Company has filed an information circular on SEDAR (the "Circular") that describes the Transaction in detail and will be...
2021-07-08 8:11 PM EDT
iCo Therapeutics Announces First Quarter 2021 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2021) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended March 31, 2021. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, CEO of iCo Therapeutics Inc., "We are very encouraged with our progress during the first quarter of 2021. We are working to...
2021-05-31 5:30 PM EDT
iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-2 Research Results at National Pharmaceutical Sciences Meeting
Vancouver, British Columbia--(Newsfile Corp. - May 11, 2021) - Amphotericin B Technologies, Inc ("Amp B Tech" or the "Company"), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) ("iCo"), announced today that two presentations related to research on the effectiveness of the Company's Oral Amphotericin B formulation ("iCo 019") on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium - Pharmaceutical Sciences in a Pandemic World. The Symposium will...
2021-05-11 8:00 AM EDT
iCo Therapeutics Announces 2020 Year End Financial Results and Resignation of Susan Koppy
Vancouver, British Columbia--(Newsfile Corp. - April 29, 2021) - iCo Therapeutics ("iCo" or the "Company") (TSXV: ICO) (OTC: ICOTF) today reported financial results for the year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").William Jarosz, CEO of iCo Therapeutics Inc., noted "We were very pleased by the progress of our Oral Amp B program during the year with our compound...
2021-04-29 5:40 PM EDT
iCo Therapeutics Inc. Announces Closing of Upsized Subscription Receipt Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTC: ICOTF) ("iCo" or the "Company") is pleased to announce that it has closed its previously announced private placement (the "Financing") in connection with its proposed business combination with Satellos Bioscience Inc. ("Satellos") by way of a plan of arrangement (the "Arrangement") in accordance with Section 192 of the Canada Business Corporations Act. The completion of the Arrangement...
2021-04-27 11:04 AM EDT
iCo Therapeutics Inc. Announces Upsized Subscription Receipt Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") is pleased to announce that, in connection with its proposed business combination with Satellos Bioscience Inc. ("Satellos") by way of a plan of arrangement (the "Arrangement"), as previously announced on March 22, 2021, it intends to offer on a private placement basis (the "Financing") 85,294,117 subscription receipts (the "Subscription Receipts") at a...
2021-04-23 8:00 AM EDT
iCo Therapeutics Inc. Agrees to a Business Combination with Satellos Bioscience Inc.
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo") and Satellos Bioscience Inc. ("Satellos"), a private Canadian corporation, together are pleased to announce the execution of a definitive agreement, dated March 21, 2021 (the "Arrangement Agreement"), providing for the business combination of iCo and Satellos by way of a plan of arrangement (the "Arrangement") in accordance with Section 192 of the Canada Business...
2021-03-22 7:00 AM EDT
iCo Therapeutics, Inc. Announces Agreement for in Vivo Testing of iCo-019 on SARS-CoV-2
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced that its wholly owned subsidiary, Amphotericin B Technologies, Inc., has entered into an agreement with IIT Research Institute to test the in vivo efficacy of iCo's novel oral amphotericin B asset ("iCo-019") against SARS-CoV-2, the causative agent of COVID-19 in the hACE2 mouse model (the "iCo-019 Study"). iCo anticipates that the iCo-019 Study...
2021-03-15 9:36 PM EDT
iCo Therapeutics Inc. Announces Warrant Exercises
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), announces that between February 1, 2021 and March 12, 2021, 20,280,000 warrants of the Company were exercised for common shares in the capital of the Company resulting in proceeds to the Company of $1,301,200.00.William Jarosz, the Chief Executive Officer of iCo commented, "We deeply appreciate this show of support from our warrant holders. These funds...
2021-03-12 8:00 AM EST
iCo Therapeutics Inc: Unaware of Any Material Change
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"). At the request of IIROC, iCo Therapeutics Inc. (the "Company") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. About iCo TherapeuticsiCo is Canadian biotechnology company principally focused on the identification, development and...
2021-02-25 3:13 PM EST
iCo Therapeutics Inc. Proposes to Re-Price Warrants
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), announces that they are submitting an application to the TSX Venture Exchange to amend the exercise price of 66,200,000 previously granted common share purchase warrants (the "Warrants") issued pursuant to a private placement of 25,000,000 units that was completed over several tranches from January 31, 2019 to March 4, 2019 (the "Spring 2019 Private...
2021-01-11 8:21 PM EST
iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), iCo Therapeutics, Inc. ("iCo") and Skymount Medical, Inc. ("Skymount") announced today that they have entered into a non-binding Memorandum of Understanding to develop iCo-019, iCo's oral Amphotericin B formulation. Skymount will initially commit up to $US 550,000 for pre-clinical work targeting the use of iCo-019 as a therapeutic product for infections...
2020-12-31 8:00 AM EST
iCo Therapeutics Announces Third Quarter 2020 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - November 24, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended September 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, CEO of iCo Therapeutics Inc., "We have aggressively continued to contain our operating expenses quarter over quarter...
2020-11-24 5:00 PM EST
iCo Therapeutics Announces Option Grants
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today granted 1,535,000 stock options to directors, officers and a contractor.The stock options are exercisable at the price of $0.05 and will expire on October 25, 2025. The stock options shall vest as follows: 1/5 on today's date (the "Effective Date") and then 1/5 every six months until all options are vested. The closing price of the Company's shares on...
2020-10-26 7:37 PM EDT
iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 - November 3rd, 2020
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that two poster presentations regarding iCo's Oral Amphotericin B technology (iCo-019) will be highlighted at the AAPS 2020 PharmSci 360 Virtual Meeting October 26 - November 5, 2020.AAPS is the preeminent global scientific organization of more than 10,000 actively participating...
2020-10-21 8:00 AM EDT
iCo Therapeutics Announces Second Quarter 2020 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended June 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, CEO of iCo Therapeutics Inc., "Our Q2 results show a marked quarter over quarter decline in our operating expenses compared...
2020-08-31 4:58 PM EDT
iCo Therapeutics Inc. Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases Journal
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today the publication of results of their Oral Amphotericin B (iCo 019) Phase 1a Study in one of the leading infectious diseases journals, Antimicrobial Agents and Chemotherapy entitled "Phase I Clinical Study to evaluate the safety, tolerability, and pharmacokinetics of a novel oral...
2020-07-30 8:57 PM EDT